FibroGen to Report Second Quarter 2021 Financial Results

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will report its second quarter 2021 financial results on August 9, following the market's close. A conference call for investors is scheduled for that day at 5:00 p.m. ET, where the company will discuss its financial performance and corporate updates. Interested participants can access the call via a live audio webcast on the FibroGen website. Additionally, a replay of the conference call will be available for 30 days after the event.

Positive

• Scheduled announcement of second quarter 2021 financial results, potentially signaling transparency and accountability.
• Opportunity for investors to engage during the conference call, enhancing investor relations.

Negative

• None.

SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Dial-In Information
Live (U.S./Canada): (877) 658-9081
Live (International): (602) 563-8732
Confirmation number: 4951789

A replay of the webcast and investor presentation will be available shortly after the call for a period of 30 days. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 4951789.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and idiopathic pulmonary fibrosis (IPF). For more information, please visit www.fibrogen.com.

Contacts: FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

Media:
GCI Health
FibroGenMedia@gcihealth.com

FAQ

When will FibroGen announce its second quarter 2021 financial results?

FibroGen will announce its second quarter 2021 financial results on August 9, 2021.

What time is the FibroGen Q2 2021 conference call scheduled?

The FibroGen Q2 2021 conference call is scheduled for 5:00 p.m. ET on August 9, 2021.

How can I access the FibroGen conference call?

The FibroGen conference call can be accessed via a live audio webcast on the FibroGen website.

Will there be a replay available for the FibroGen conference call?

Yes, a replay of the FibroGen conference call will be available for 30 days after the event.

What is the ticker symbol for FibroGen?

The ticker symbol for FibroGen is FGEN.